Also found in: Acronyms, Wikipedia.


 (dī′kăst′, dĭk′ăst′)
One of the 6,000 citizens chosen each year in ancient Athens to sit in the law courts, with functions resembling those of a judge and juror.

[Greek dikastēs, judge, from dikazein, to judge, from dikē, right, custom; see deik- in Indo-European roots.]

di·cas′tic adj.


1. (Historical Terms) (in ancient Athens) a juror in the popular courts chosen by lot from a list of citizens
2. (Law) (in ancient Athens) a juror in the popular courts chosen by lot from a list of citizens
[C19: from Greek dikastēs, from dikazein to judge, from dikē right, judgment, order]
diˈcastic adj


(ˈdaɪ kæst, ˈdɪk æst)

(in ancient Athens) one of 6000 citizens chosen by lot each year to sit as a judge.
[1700–10; < Greek dikastḗs]
Mentioned in ?
References in classic literature ?
And this is the reason why in our State, and in our State only, we shall find a shoemaker to be a shoemaker and not a pilot also, and a husbandman to be a husbandman and not a dicast also, and a soldier a soldier and not a trader also, and the same throughout?
and HuMabs programs, while unlocking new growth opportunities for the Company, such as the option agreement for DiCAST.
our late-stage immunotherapy asset, and extends to our HuMabs and DiCAST programs, both of which hold significant promise on their own and to potential future partners.
Morsing was instrumental in pursuing and securing the option agreement for DiCAST and establishing the Company's Ireland Research Centre.
QB: VGEN), a cancer immunotherapy development company, announced today it has entered into an exclusive option agreement with Dublin City University (DCU), through one of its subsidiaries, that provides the Company with an exclusive two-year option to evaluate and acquire a revolutionary high-throughput, multiplex, analysis platform -- DiCAST.
Vaccinogen intends to utilize DiCAST to expand and significantly accelerate the Company's human monoclonal antibody (HuMab) program, screening patient-derived biological samples acquired after gaining anti-cancer immunity.
OpTech acquired exclusive rights and title to all IOS technologies, past, present and future, including optical sensing-based security systems and products using the DICAST technology.